Mach7 Technologies Ltd. · ASX:M7T
Mach7 Technologies — H1 FY2022 Earnings Presentation
14 slides from Mach7 Technologies's earnings presentation, Feb 28, 2022
Slide 1: 1H FY22 Results Presentation
For personal use only 1H FY22 Results Presentation February 28, 2022 Mach7 Technologies ASX: M7T 1
Slide 2: Disclaimer "forward looking" statements
Disclaimer “forward looking” statements Summary of information: This presentation contains general and background information about Mach7 Risks: An investment in M7T securities is subject to investment and other known and unknown risks, For personal use only Technologies Limited (“M7T”) activities c
Slide 3: Company Highlights
Company Highlights Mach7 is a clear market leader in the provision of a complete enterprise imaging solution, For personal use only encompassing imaging data management (vendor neutral archive and data administration tools), departmental workflow applications and a powerful enterprise and diagnostic
Slide 4: First-half highlights
First-half highlights For personal use only Record Sales Order Significant contract Record EBITDA Contracted Annual growth (TCV) wins from US premier $3.1M Recurring first half 22.1M healthcare providers – +$6.3M or 192% PCP Revenue (CARR) +$11.3M or 206% PCP* Advocate Aurora $4.4M $16.8M Trinity He
Slide 5: Strong Sales Order Growth
Strong Sales Order Growth For personal use only SALES ORDERS – AUD* Highlights: • Sales growth is continuing to build from a 22.1M 15.6M record FY21 of $25M • $22.1M sales orders 1HFY22 (up 206% from $10.7M PCP). 10.7M • Pipeline is continuing to build with an increasing interest coming in the form
Slide 6: Revenue
Revenue Strong Revenue growth across all segments For personal use only 1H 2022 1H 2021 % Change Highlights: Enterprise Diagnostic • +100% growth in both Diagnostic Viewing (eUnity) 5.4 M 2.7 M 100% Viewing (eUnity) and Data Management (VNA) segments Enterprise Data 8.9 M 4.4 M 102% Management (VNA)
Slide 7: EBITDA
EBITDA Improved Gross Margins & synergies realized will increase profitability for 2H 22 For personal use only 1H 2022 1H 2021 % Change Highlights: • Gross margins will continue to improve Revenues 14.3 M 7.1 M +102% as 3D capability is developed in-house • Operating expenses of $10.7M for 1H expect
Slide 8: Awards and Publications
Awards and Publications For personal use only Frost & Industry Tech CIO Sullivan Insights Review 2021 Global Enterprise 2021 Top 10 Companies 2021 Top 20 Most Imaging Solutions Product Revolutionizing Promising Workflow Leadership Award Healthcare Solution Providers 8
Slide 9: KLAS – Defined
KLAS – Defined The Best in KLAS report recognizes software and services companies who excel For personal use only in helping healthcare professionals improve patient care. KLAS surveys’ healthcare IT customers (providers) throughout Best in KLAS is highly competitive and the calendar year and releas
Slide 10: Recognition of Mach7
Recognition of Mach7 For personal use only Best in KLAS Best in KLAS CIO 2022 Report 2022 Report Bulletin #2 #3 50 Most Influential Companies of the Year 2022 Industry Performer Industry Performer To be published in April 2022 Universal Viewer Vendor Neutral Archive 10
Slide 11: Mach7 Performance: Best in KLAS 2022 - Universal Viewer
Mach7 Performance For personal use only Best in KLAS 2022- Universal Viewer #2 Vaulted to #2 overall ranking in Market #1 Held the #1 spot for most of CY 2021 Currently (as of Feb 9, 2022) #1 in #1 rank Notable performance is a 95% 95% score for “Would you buy again.” Industry average is 84% 11
Slide 12: Mach7 Performance: Best in KLAS 2022 - VNA
Mach7 Performance For personal use only Best in KLAS 2022 - VNA Mach7 springs out of Limited Data #3 segment to #3 in performance “Solution Comparison” listing. Mach7 goes from 7 to 18 distinct site survey respondents showing significantly increased customer engagement and attachment. Outperforming
Slide 13: Outlook
Outlook For personal use only Growing Strong sales Award-winning Building up optimism performance products our business Growing optimism Strong 1H, which we Highly acclaimed FY2021 was about within the Healthcare expect to continue in products being building up our business IT sector. Emphasized 2H.
Slide 14: Contact us
For personal use only Contact us CEO, Mach7: Mike Lampron mike.lampron@mach7t.com CFO, Mach7: Steve Parkes steve.parkes@mach7t.com Investor Relations: Simon Hinsley, NWR Communications +61 (0) 401 809 653 simon@nwrcommunications.com.au Registered Office: Level 4 | 100 Albert Road South Melbourne, VI